IPO Tracker

Life sciences companies face unique issues in accessing capital markets, including matters related to due diligence, public relations, regulatory and intellectual property. Goodwin offers a team of sophisticated life sciences lawyers who have expertise with these issues and extensive experience across the full breadth of equity and debt capital markets, advising issuers, sponsors, underwriters and investors in a variety of transactions to ensure deals close smoothly and in a timely way.

With over 150 lawyers focused on serving over 600 life sciences clients, our integrated, full service life sciences team offers deep transactional expertise drawing on firm resources spread across the globe. Since 2010, the firm has advised on more than 150 emerging company IPOs raising an excess of $25 billion. Over the years, Goodwin has been ranked among the top law firms for biotech IPOs issuer representation. In the past two years, Goodwin has advised twenty three biotechnology issuers on their IPOs totaling an aggregate of $4.1 billion.

Company Name
Company
Focus
Underwriters
IPO Date
Offer Price to the Public
Aggregate Offering Raise
Original Price Range
Goodwin Participation,
if applicable
Codiak Biosciences
(NASDAQ: CDAK)
Therapeutics using exosome biology Goldman Sachs
Evercore
William Blair
Wedbush Securities
10/13/2020
S-1
$15 $82.5 million $14-$16 Issuer
Kronos Bio
(NASDAQ: KRON)
Cancer therapeutics Goldman Sachs
Jefferies
Cowen & Co.
Piper Sandler
10/8/2020
S-1
$19 $287.5 million $16-$18
Shattuck Labs
(NASDAQ: STTK)
Immuno-oncology protein therapies Citigroup
Cowen & Co.
Evercore
Needham
10/8/2020
S-1
$17 $232.3 million $14-$16
Spruce Biosciences
(NASDAQ: SPRB)
Endocrine disorder therapies Cowen & Co.
SVB Leerink
Credit Suisse
RBC Capital Markets
10/8/2020
S-1
$15 $103.5 million $14-$16
Aziyo Biologics
(NASDAQ: AZYO)
Tissue regenerating medical products Piper Sandler
Cowen & Co.
Cantor Fitzgerald
Truist Securities
10/7/2020
S-1
$17 $50 million $16-$18
C4 Therapeutics
(NASDAQ: CCCC)
Drugs to destroy target proteins Jefferies
Evercore
BMO Capital Markets
UBS
10/1/2020
S-1
$19 $209.76 million $16-$18 Issuer
Immunome
(NASDAQ: IMNM)
Antibody therapeutics Ladenburg Thalmann
Chardan Capital Markets
10/1/2020
S-1
$12 $44.85 million $11-$13 Underwriter
Oncorus
(NASDAQ: ONCR)
Viral immunotherapies for cancer Jefferies
Evercore
Piper Sandler
10/1/2020
S-1
$15 $87 million $14-$16
Orphazyme
(NASDAQ: ORPH)
Neurodegenerative disease therapies BofA Securities
Cowen & Co.
Guggenheim
Danske Markets
9/28/2020
F-1
$11 $50.17 million $13.13
Graybug Vision
(NASDAQ: GRAY)
Medicines to treat ocular diseases SVB Leerink
Piper Sandler
9/24/2020
S-1
$16 $90 million $15-$17
PMV Pharmaceuticals (NASDAQ: PMVP) Tumor-agnostic cancer therapies Goldman Sachs
BofA Securities
Cowen & Co.
Evercore Group
9/24/2020
S-1
$18 $243.53 million $16-$18
Prelude Therapeutics (NASDAQ: PRLD) Small molecule cancer therapies Morgan Stanley
Goldman Sachs
BofA Securities
9/24/2020
S-1
$19 $181.90 million $17-$19
Taysha Gene Therapies
(NASDAQ: TSHA)
Therapies for monogenic diseases Goldman Sachs
Morgan Stanley
Jefferies
9/23/2020
S-1
$20 $181 million $18-$20 Underwriter
Athira Pharma
(NASDAQ: ATHA)
Therapeutics for neurological diseases Goldman Sachs
Jefferies
Stifel Nicolaus
9/17/2020
S-1
$17 $204 million $15-$17
COMPASS Pathways
(NASDAQ: CMPS)
Psilocybin therapies for depression Cowen & Co.
Evercore
Berenberg Capital Markets
9/17/2020
F-1
$17 $146.60 million $14-$16 Issuer
Athira Pharma
(NASDAQ: ATHA)
Therapeutics for neurological diseases Goldman Sachs
Jefferies
Stifel Nicolaus
9/17/2020
S-1
$17 $204 million $15-$17
Dyne Therapeutics
(NASDAQ: DYN)
Therapies for genetic muscular diseases J.P. Morgan
Jefferies
Piper Sandler
Stifel Nicolaus
9/16/2020
S-1
$19 $268 million $16-$18
Metacrine
(NASDAQ: MTCR)
Liver and gastrointestinal therapies Jefferies
Evercore
RBC Capital Markets
Canaccord Genuity
9/15/2020
S-1
$13 $85.02 million $12-$14
Kymera Therapeutics (NASDAQ: KYMR) Small molecule protein degraders Morgan Stanley
BofA Securities
Cowen & Co.
Guggenheim
8/20/2020
S-1
$20 $199.75 million $16-$18 Issuer
Harmony Biosciences (NASDAQ: HRMY) Therapies for neurological disorders Goldman Sachs
Jefferies
Piper Sandler
8/18/2020
S-1
$24 $147.62 million $20-$23 Underwriter
Inhibrx
(NASDAQ: INBX)
Protein therapies to treat cancer Jefferies
Evercore
Credit Suisse
8/18/2020
S-1
$17 $136.85 million $16-$18
CureVac
(NASDAQ: CVAC)
Messenger RNA-based therapies BofA Securities
Jefferies
Credit Suisse
8/13/2020
F-1
$16 $245.33 million $14-$16
Checkmate Pharmaceuticals
(NASDAQ: CMPI)
Therapeutics to treat cancer BofA Securities
Jefferies
BMO Capital Markets
8/06/2020
S-1
$15 $75 million $14-$16 Issuer
Freeline Therapeutics
(NASDAQ: FRLN)
Gene therapies for monogenic diseases J.P. Morgan
Morgan Stanley
Evercore
8/06/2020
F-1
$18 $158.82 million $16-$18 Underwriter
Acutus Medical
(NASDAQ: AFIB)
Cardiac arrhythmia treatments J.P. Morgan
BofA Securities
William Blair
8/05/2020
S-1
$18 $182.64 million $16-$18
Oak Street Health
(NYSE: OSH)
Healthcare for adults on Medicare J.P. Morgan
Goldman Sachs
Morgan Stanley
8/05/2020
S-1
$21 $377.34 million $15-$17
AlloVir
(NASDAQ: ALVR)
Allogenic T cell therapies Morgan Stanley
J.P. Morgan
SVB Leerink
Piper Sandler
7/29/2020
S-1
$17 $317.68 million $16-$18 Issuer
Annexon
(NASDAQ: ANNX)
Complement-mediated disorder therapies J.P. Morgan
BofA Securities
Cowen & Co.
7/23/2020
S-1
$17 $288.36 million $14-$16
Inozyme Pharma
(NASDAQ: INZY)
Treatments for abnormal mineralization BofA Securities
Cowen & Co.
Piper Sandler
7/23/2020
S-1
$16 $128.8 million $14-$16
iTeos Therapeutics
(NASDAQ: ITOS)
Immuno-oncology therapeutics J.P. Morgan
SVB Leerink
Piper Sandler
7/23/2020
S-1
$19 $231.31 million $16-$18 Issuer
Nurix Therapeutics
(NASDAQ: NRIX)
Small molecule immuno-oncology agents J.P. Morgan
Piper Sandler
Stifel Nicolaus
7/23/2020
S-1
$19 $240.35 million $16-$18
ALX Oncology
(NASDAQ: ALXO)
Immuno-oncology therapies Jefferies
Credit Suisse
Piper Sandler
Cantor Fitzgerald
7/16/2020
S-1
$19 $185.7 million $15-$17
Berkeley Lights
(NASDAQ: BLI)
Biotherapeutics and cell-based products J.P. Morgan
Morgan Stanley
Cowen & Co.
7/16/2020
S-1
$22 $204.9 million $16-$18
Pandion Therapeutics
(NASDAQ: PAND)
Therapeutics for autoimmune diseases Goldman Sachs
Morgan Stanley
SVB Leerink
BMO Capital Markets
7/16/2020
S-1
$18 $135 million $16-$18 Underwriter
Renalytix AI
(NASDAQ: RNLX)
AI-enabled in vitro diagnostics J.P. Morgan
Sitfel Nicolaus
7/16/2020
F-1
$13.50 $85.1 million $14.22 Underwriter
Relay Therapeutics
(NASDAQ: RLAY)
Small molecule therapeutics for cancer J.P. Morgan
Goldman Sachs
Cowen & Co. Guggenheim
7/15/2020
S-1
$20 $460 million $16-$18 Issuer
Inventiva
(NASDAQ: IVA)
Non-alcoholic fatty liver treatments Jefferies
Stifel Nicolaus
Guggenheim 
7/09/2020
F-1
$14.40 $123.8 million $13.68
NKarta
(NASDAQ: NKTX)
Natural killer cell cancer therapies Cowen & Co.
Evercore
Stifel Nicolaus
Mizuho 
7/09/2020
S-1
$18 $289.8 million $14-1$16
Poseida Therapeutics
(NASDAQ: PSTX)
Cell and gene therapeutics BofA Securities
Piper Sandler
William Blair
7/09/2020
S-1
$16 $257.6 million $14-$16
Akouos, Inc.
NASDAQ (AKUS)
Gene therapies for hearing loss BofA Securities
Cowen & Co.
Piper Sandler
06/25/2020
S-1
$17.00 $244.37
million
$14.00 –
$16.00
 
Forma Therapeutics Holdings, Inc.
NASDAQ (FMTX)
Cancer & hematologic disease therapies Jefferies
SVB Leerink
Credit Suisse
06/25/2020
S-1
$20.00 $319.29
million
$16.00 –
$18.00
Issuer
PolyPid Ltd.
NASDAQ (PYPD)
Therapies to improve surgical outcomes Barclays Capital
BMO Capital Markets
Raymond James
06/25/2020
F-1 
$16.00  $69.00
million  
$15.00 –
$17.00 
 
Progenity, Inc.
NASDAQ (PROG)
Molecular testing products Piper Sandler
Wells Fargo Securities
06/19/2020
S-1
$15.00 $115.00
million
$14.00 –
$16.00 
 
Repare Therapeutics Inc.
NASDAQ (RPTX)
Genomic-focused cancer therapies Morgan Stanley
Goldman Sachs
Cowen & Co.
Piper Sandler
06/18/2020
S-1
$20.00 $253.00
million
$16.00 –
$18.00
Underwriter
Genetron Holdings Limited
NASDAQ (GTH)
Cancer molecular profiling technologies Credit Suisse
China International Capital Corporation
06/18/2020
F-1
$16.00 $294.4
million
$11.50 –
$13.50
 
Royalty Pharma plc
NASDAQ (RPRX)
Biopharmaceutical royalties acquisition J.P. Morgan
Morgan Stanley
BofA Securities
Goldman Sachs
Citigroup
UBS Securities
06/15/2020
S-1
$28.00 $2.5
billion
$25.00 –
$28.00
Underwriter
Avidity Biosciences, Inc.
NASDAQ (RNA)
Therapeutics to treat serious diseases Cowen & Co.
SVB Leerink
Credit Suisse
Wells Fargo Securities
06/11/2020
S-1
$18.00 $298.08
million
$14.00 –
$16.00 
 
Burning Rock Biotech Limited
NASDAQ (BNR)
Cancer therapy selection services Morgan Stanley
BofA Securities
Cowen & Co.
06/11/2020
F-1
$16.50 $256.16
million
$13.50 –
$15.50 
 
Generation Bio Co.
NASDAQ (GBIO)
Non-viral gene therapies J.P. Morgan
Jefferies
Cowen & Co.
Wedbush Securities
06/11/2020
S-1
$19.00 $229.99
million
$16.00 –
$18.00 
 
Vaxcyte, Inc.
NASDAQ (PCVX)
Pneumococcal conjugate vaccines BofA Securities
Jefferies
Evercore Group
06/11/2020
S-1
$16.00 $287.50
million
$14.00 –
$16.00 
 
Fusion Pharmaceuticals Inc.
NASDAQ (FUSN)
Radiopharmaceuticals to treat cancers Morgan Stanley
Jefferies
Cowen & Co.
06/05/2020
S-1
$17.00 $244.37
million
$14.00 –
$16.00
Issuer
Legend Biotech Corporation
NASDAQ (LEGN)
Cell therapies to treat cancer Morgan Stanley
J.P. Morgan
Jefferies
06/05/2020
F-1
$23.00  $487.34
million
$18.00 –
$20.00  
 
Applied Molecular Transport Inc.
NASDAQ (AMTI)
Oral biologic products to treat disease BofA Securities
Jefferies
SVB Leerink
06/04/2020
S-1
$14.00 $177.10 million $12.00 – $14.00   
Calliditas Therapeutics
NASDAQ (CALT)
Treatment for  autoimmune renal disease  Citigroup
Jefferies
Stifel, Nicolaus 
06/04/2020
F-1 
$19.50 $90.00
million  
$19.77 Issuer
Pliant Therapeutics, Inc. 
NASDAQ (PLRX)
Fibrosis therapeutics Citigroup
Cowen & Co.
Piper Sandler
06/02/2020
S-1
$16.00 $165.60
million
$14.00-
$16.00
Issuer
Inari Medical, Inc.
NASDAQ (NARI)
Thrombectomy devices BofA Securities
Morgan Stanley
05/21/2020
S-1
$19.00 $179.22
million
$14.00 –
$16.00 
 
ADC Therapeutics SA
NASDAQ (ADCT)
Blood cancer therapies Morgan Stanley
BofA Securities
Cowen & Co.
05/14/2020
F-1
$19.00 $267.56
million
$16.00 –
$18.00 
 
Ayala Pharmaceuticals, Inc.
NASDAQ (AYLA)
Small molecule therapies for cancer Citigroup
Jefferies
05/07/2020
S-1
$15.00 $63.25
million
$14.00-
$16.00 
 
Lyra Therapeutics, Inc.
NASDAQ (LYRA)
Localized ear, nose & throat treatments BofA Securities
Jefferies
William Blair
04/30/2020
S-1
$16.00 $64.40
million
$14.00 –
$16.00 
 
ORIC Pharmaceuticals, Inc.
NASDAQ (ORIC)
Therapies to treat cancer J.P. Morgan
Citigroup
Jefferies
Guggenheim 
04/23/2020
S-1
$16.00 $138.00
million
$14.00-
$16.00 
 
Keros Therapeutics, Inc.
NASDAQ (KROS)
Treatment for hematological disorders Jefferies
SVB Leerink
Piper Sandler
04/07/2020
S-1
$16.00 $110.40
million
$14.00-
$16.00 
 
Zentalis Pharmaceuticals, Inc.
NASDAQ (ZNTL)
Small molecule cancer therapies Morgan Stanley
Jefferies
SVB Leerink
Guggenheim 
04/02/2020
S-1
$18.00 $190.02
million
$16.00 –
$18.00 
 
IMARA Inc.
NASDAQ (IMRA)
Therapies for hemoglobinopathies Morgan Stanley
Citigroup
SVB Leerink
03/11/2020
S-1
$16.00 $86.48
million
$16.00 –
$18.00 
 
Passage Bio, Inc.
NASDAQ (PASG)
CNS disorder therapies J.P. Morgan
Goldman Sachs
Cowen & Co.
02/27/2020
S-1
$18.00 $248.4
million
$16.00 –
$18.00 
 
Revolution Medicines, Inc.
NASDAQ (RVMD)
Protein therapies to treat cancer J.P. Morgan
Cowen & Co.
SVB Leerink
Guggenheim 
02/12/2020
S-1
$17.00 $273.7
million
$14.00-
$16.00 
 
Beam Therapeutics, Inc.
NASDAQ (BEAM)
Gene Editing J.P. Morgan
Jefferies
Barclays Capital
02/05/2020
S-1
$17.00 $207
million
$15.00 –
$17.00
 
PPD, Inc.
NASDAQ (PPD)
Drug development & laboratory svcs Barclays Capital
J.P. Morgan
Morgan Stanley
Goldman Sachs 
02/05/2020
S-1
$27.00 $1.80
billion
$24.00 –
$27.00
 
1Life Healthcare
NASDAQ (ONEM)
Digital healthcare platform J.P. Morgan
Morgan Stanley
01/30/2020
S-1
$14.00 $281.00
million
$14.00 –
$16.00
 
Arcutis Biotherapeutics, Inc.
NASDAQ (ARQT)
Treatments for dermatological diseases Goldman Sachs
Cowen & Co.
Guggenheim
01/30/2020
S-1
$17.00 $183.28
million
$15.00 –
$17.00
 
Black Diamond Therapeutics
NASDAQ (BDTX)
Small molecule tumor-agnostic therapies J.P. Morgan
Jefferies
Cowen & Co.
01/29/2020
S-1
$19.00 $231.3
million
$16.00 –
$18.00
Issuer
I-Mab
NASDAQ (IMAB)
Drugs for cancers & autoimmune diseases Jefferies
China International Capital Corporation
01/16/2020
F-1
$14.00 $119.25
million
$12.00 –
$15.00